Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.48 |
| ▸ | HTR7 | P34969 | 7/20 | 0.48 |
| ▸ | HTR6 | P50406 | 7/20 | 0.48 |
| ▸ | SORD | Q00796 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23074532 | 0.91 | HTR2A (0.47) | HTR2AHTR7HTR6SORDDRD2 | |
| SCHEMBL23064393 | 0.81 | HTR7 (0.49) | HTR2AHTR7HTR6SORDDRD2 | |
| SCHEMBL30778015 | 0.81 | HTR7 (0.49) | HTR2AHTR7HTR6SORDDRD2 | |
| SCHEMBL23064319 | 0.79 | SORD (0.50) | HTR2AHTR7HTR6SORDDRD2 | |
| SCHEMBL30778007 | 0.79 | SORD (0.50) | HTR2AHTR7HTR6SORDDRD2 | |
| SCHEMBL9377818 | 0.78 | HPGD (0.55) | HTR2AHTR7SORDDRD2HTR1A | |
| SCHEMBL23074528 | 0.78 | HTR7 (0.47) | HTR2AHTR7HTR6SORDDRD2 | |
| SCHEMBL14046594 | 0.77 | SORD (0.54) | HTR2AHTR7SORDDRD2HTR1A | |
| SCHEMBL458698 | 0.77 | HPGD (0.58) | HTR2ASORDDRD2HTR1ADRD4 | |
| SCHEMBL23064375 | 0.76 | SORD (0.53) | HTR2AHTR7HTR6SORDDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170116-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | OSAKA UNIVERSITY (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250073229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | SHINSHU UNIVERSITY (JP) | 2025-03-06 | — | — | US | disclosed |
| EP-4487848-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | OSAKA UNIVERSITY (JP) | 2025-01-08 | — | — | EP | disclosed |
| EP-4461296-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | Osaka University (JP) | 2024-11-13 | — | — | EP | disclosed |
| CN-118678955-A | Pharmaceutical composition for preventing and/or treating heart failure | 国立大学法人大阪大学 | 2024-09-20 | — | — | CN | disclosed |
| US-20240307375-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | KYOTO UNIVERSITY (JP) | 2024-09-19 | — | — | US | disclosed |
| CN-112204017-B | Benzisoxazole compounds | 国立大学法人大阪大学 | 2024-08-20 | — | — | CN | disclosed |
| EP-4364739-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | OSAKA UNIVERSITY (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-11976062-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2024-05-07 | — | — | US | disclosed |
| EP-3789383-B9 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023132208-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | 国立大学法人大阪大学 | 2023-07-13 | — | — | WO | disclosed |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | KYOTO UNIVERSITY (JP) | 2023-04-13 | — | — | US | disclosed |
| US-11548882-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2023-01-10 | — | — | US | disclosed |
| US-11548882-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2023-01-10 | — | — | US | disclosed |
| WO-2023276828-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | 国立大学法人大阪大学 | 2023-01-05 | — | — | WO | disclosed |
| US-20210238171-A1 | BENZISOXAZOLE COMPOUND | INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES (JP) | 2021-08-05 | — | — | US | disclosed |
| US-20210238171-A1 | BENZISOXAZOLE COMPOUND | INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES (JP) | 2021-08-05 | — | — | US | disclosed |
| WO-2021079962-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF HEARING LOSS | 国立大学法人大阪大学 | 2021-04-29 | — | — | WO | disclosed |
| EP-3789383-A1 | BENZISOXAZOLE COMPOUND | Osaka University (JP) | 2021-03-10 | — | — | EP | disclosed |
| CN-112204017-A | Benzisoxazole compounds | 国立大学法人大阪大学 | 2021-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238171-A1 | BENZISOXAZOLE COMPOUND | CBR1, CYP2S1, CYP2E1 | HTR2A 4776/4885HTR7 4212/4885HTR6 4813/4885 |
| US-20240307375-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | ATG7, BECN1, SQSTM1 | HTR2A 2633/4885HTR7 2928/4885HTR6 3563/4885 |
| US-11976062-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | HTR2A 4780/4885HTR7 4231/4885HTR6 4812/4885 |
| US-20250170116-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | REN, ATP6V1B1, CYP2S1 | HTR2A 3869/4885HTR7 4099/4885HTR6 4120/4885 |
| US-11548882-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | HTR2A 4776/4885HTR7 4212/4885HTR6 4813/4885 |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | CBR1, CYP2S1, CYP2E1 | HTR2A 4738/4885HTR7 4073/4885HTR6 4756/4885 |
| US-20250073229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | CBR1, CYP2S1, CYP2F1 | HTR2A 3378/4885HTR7 3815/4885HTR6 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.